Changeflow GovPing Healthcare & Life Sciences USPTO Patent Grant: Composition for Improving M...
Routine Notice Added Final

USPTO Patent Grant: Composition for Improving Muscle Function

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

The USPTO has granted patent US12582623B2 to N.V. Nutricia for a composition comprising EPA, MA, and leucine. This composition is intended for the prevention and/or treatment of diseases involving muscle decline or for improving muscle function.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12582623B2, titled 'Composition comprising EPA, MA and leucine for improving muscle function,' to N.V. Nutricia. The patent covers compositions containing eicosapentaenoic acid (EPA), methyl arachidonate (MA), and leucine, aimed at preventing or treating conditions associated with muscle decline and enhancing muscle function.

This patent grant signifies the USPTO's recognition of novel intellectual property in the therapeutic and nutritional space. While patent grants are not direct regulatory mandates for compliance, they represent innovation in drug and supplement development. Companies operating in the pharmaceutical and nutraceutical sectors should be aware of this granted patent, particularly if their research or product development involves similar compositions or targets muscle health.

Archived snapshot

Mar 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Composition comprising EPA, MA and leucine for improving muscle function

Grant US12582623B2 Kind: B2 Mar 24, 2026

Assignee

N.V. Nutricia

Inventors

Miriam van Dijk-Ottens, Francina Jeannette Dijk

Abstract

The invention relates to compositions comprising EPA, MA and leucine for prevention and/or treatment of a disease or condition involving muscle decline or for improving muscle function.

CPC Classifications

A61K 31/198 A61K 31/20 A61K 31/202 A23L 33/12 A23L 33/175 A23L 33/19 A61P 3/02

Filing Date

2020-10-30

Application No.

17770634

Claims

15

View original document →

Named provisions

Composition comprising EPA, MA and leucine for improving muscle function

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 24th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US12582623B2

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3114 Food & Beverage Manufacturing
Activity scope
Drug Development Nutritional Supplement Formulation
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
R&D
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Development Nutritional Science

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!